Loading data
HLIONYSE
| Unit: USD | FY2026 | FY2024 | FY2023 | FY2023 | FY2022 | FY2022 |
|---|---|---|---|---|---|---|
| Revenue | 839 m USD | 805.9 m USD | — | 835.6 m USD | 885.4 m USD | — |
| Cost of revenue | 567.8 m USD | 553.6 m USD | — | 573.9 m USD | 586.9 m USD | — |
| Gross profit | 271.2 m USD | 252.3 m USD | — | 261.7 m USD | 298.5 m USD | — |
| Research and development expense | 19.1 m USD | 20.1 m USD | — | 19.2 m USD | 17.4 m USD | — |
| Selling, general and administrative expense | 147.6 m USD | 139 m USD | — | 148.9 m USD | 133.1 m USD | — |
| Operating profit | 66 m USD | 81.8 m USD | — | 79.9 m USD | 137.3 m USD | — |
| Profit before tax | 62.4 m USD | 50.5 m USD | — | 49.2 m USD | 121.8 m USD | — |
| Income tax expense | 14 m USD | 11.5 m USD | — | 11.7 m USD | 23.4 m USD | — |
| Net income (reported basis) | 48.4 m USD | 39 m USD | 37.5 m USD | 37.5 m USD | 98.4 m USD | 98.4 m USD |
| Basic earnings per share | 1.46 USD/share | 1.17 USD/share | — | 1.14 USD/share | 3.03 USD/share | — |
| Diluted earnings per share | 1.45 USD/share | 1.17 USD/share | — | 1.14 USD/share | 3.02 USD/share | — |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.